Genemarkers has been providing high-quality clinical genetic testing since 2014. As a pioneer in the pharmacogenomic (PGx) testing industry, Genemarkers remains committed to creating tests that include drug-gene pairs with the highest levels of clinical validity and utility. We know healthcare providers count on us to supply reliable test data to guide their prescribing.
In response to recent changes in Centers for Medicare & Medicaid Services (CMS) and other payer guidelines, and to meet the needs of our patients, we have updated our test panels. Genemarkers will be offering three multigene pharmacogenomic (PGx) panels and two single gene tests. Our updated test panels include drug-gene pairs for which the Food and Drug Administration (FDA) and the Clinical Pharmacogenomics Implementation Consortium (CPIC) have recognized as having scientific evidence to support clinical use. Our PGXMarkers Plus panel also includes drug-gene pairs for which recommendations are informative, meaning that implementation in a clinical setting is optional. The updated panels will be available in May of 2022.
PsychPainMarkers
The PsychPainMarkers Panel helps providers make prescribing decisions for many of the most frequently used psychotropic and pain medications. PsychPainMarkers tests for variants in 3 genes that are associated with the efficacy and toxicity of 49 medications. Some medications on the PsychPainMarkers Panel include Sertraline (Zoloft©), Fluoxetine (Prozac©), Escitalopram (Lexapro©), Ibuprofen (Motrin©, Advil©), Hydrocodone (Vicodin©), Tramadol (Ultram©), and more.
PGXMarkers
The PGXMarkers Panel tests 6 genes and gives providers insight into 89 different medications. Like PsychPainMarkers, all recommendations in this report only contain drug-gene pairs for which there is actionable clinical guidance as determined by the FDA and CPIC. The PGXMarkers panel covers medications used in cardiology, gastroenterology, neurology, psychiatry, and other areas of clinical practice. In addition to those in the PsychPainMarkers test, PGXMarkers includes additional medications such as Simvastatin (Zocor©), Ondansetron (Zofran©), and Darifenacin (Enablex©).
PGXMarkers Plus
The PGXMarkers Plus Panel is the most comprehensive of Genemarkers’ panels and includes information on 18 genes and 138 medications. The PGXMarkers Plus Panel contains drug-gene pairs for which there is both actionable and informative guidance. Some medications found exclusively on the PGXMarkers Plus Panel include Morphine (MS Contin©), Methadone (Dolophine©), Fentanyl (Actiq©), and Bupropion (Wellbutrin©, Zyban©, Aplenzin©, Contrave©), among others.
Single Gene Tests
In addition to the PGx panels described above, Genemarkers now offers two single gene tests: one that tests for genetic variants known to affect the efficacy and toxicity of Plavix© and one for genetic variants in methylfolate reductase (MTHFR), associated with Hyperhomocysteinemia.